EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment of Diet-Induced Obese Rats with CB2 Agonist AM1241 or CB2 Antagonist AM630 Reduces Leptin and Alters Thermogenic mRNA in Adipose Tissue

Lannie O'Keefe iD, Teresa Vu, Anna C Simcocks, Kayte A Jenkin, Michael L Mathai, Andrew J McAinch iD, Dana S Hutchinson, Deanne H Hryciw iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24087601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lannie O'Keefe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health and Sport, Victoria University, P.O. Box 14428, Melbourne, VIC 8001, Australia. Hauptthemen laut MEDLINE: Leptin, Cannabinoids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allen Foundation, Australian Rotary Health Scholarship, Griffith University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diet-induced obesity (DIO) is a contributor to co-morbidities, resulting in alterations in hormones, lipids, and low-grade inflammation, with the cannabinoid type 2 receptor (CB2) contributing to the inflammatory response. The effects of modulating CB2 with pharmacological treatments on inflammation and adaptations to the obese state are not known. Therefore, we aimed to investigate the molecular mechanisms in adipose tissue of CB2 agonism and CB2 antagonism treatment in a DIO model. Male Sprague Dawley rats were placed on a high-fat diet (HFD) (21% fat) for 9 weeks, then received daily intraperitoneal injections with a vehicle, AM630 (0.3 mg/kg), or AM1241 (3 mg/kg), for a further 6 weeks. AM630 or AM1241 treatment in DIO rats did not alter their body weight, food intake, or liver weight, and it had no effect on their numerous circulating cytokines or peri-renal fat pad mass. AM1241 decreased heart weight and BAT weight; both treatments (AM630 or AM1241) decreased plasma leptin levels, while AM630 also decreased plasma ghrelin and GLP-1 levels. Both treatments decreased Adrb3 and TNF-α mRNA levels in eWAT and TNF-α levels in pWAT. AM630 treatment also decreased the mRNA levels of Cnr2, leptin, and Slc2a4 in eWAT. In BAT, both treatments decreased leptin, UCP1, and Slc2a4 mRNA levels, with AM1241 also decreasing Adrb3, IL1β, and PRDM16 mRNA levels, and AM630 increasing IL6 mRNA levels. In DIO, CB2 agonist and CB2 antagonist treatment reduces circulating leptin in the absence of weight loss and modulates the mRNA responsible for thermogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeptinCannabinoidsRatsMaleAnimalsTumor Necrosis Factor-alphaRNA, MessengerRats, Sprague-DawleyObesityAdipose TissueReceptors, CannabinoidDiet, High-FatInflammationThermogenesisReceptor, Cannabinoid, CB2Indoles

Stichwörter der Autor:innen

AM1241AM630adipose tissuecannabinoid receptor 2 (CB2)diet-induced obesity (DIO)endocannabinoid system (ECS)inflammation

Substanzen

LeptinTumor Necrosis Factor-alphaRNA, MessengerCannabinoidsReceptors, CannabinoidReceptor, Cannabinoid, CB2AM 1241iodopravadolineIndoles

Autor:innen und Institutionen

  • Institute for Health and Sport, Victoria University, P.O. Box 14428, Melbourne, VIC 8001, Australia.
  • Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
  • School of Science, Western Sydney University, Campbelltown, NSW 2560, Australia.
  • The Florey Institute of Neuroscience and Mental Health, Parkville, VIC 3052, Australia.
  • Australian Institute for Musculoskeletal Science (AIMSS), Victoria University, Melbourne, VIC 8001, Australia.
  • School of Environment and Sciences, Griffith University, Nathan, QLD 4111, Australia.

ORCID-Profile: Lannie O'Keefe, Andrew J McAinch, Deanne H Hryciw

Förderung

  • Allen Foundation
  • Australian Rotary Health Scholarship
  • Griffith University

Zitieren

APA

O'Keefe, L., Vu, T., Simcocks, A. C., Jenkin, K. A., Mathai, M. L., McAinch, A. J., Hutchinson, D. S., & Hryciw, D. H. (2023). Treatment of Diet-Induced Obese Rats with CB2 Agonist AM1241 or CB2 Antagonist AM630 Reduces Leptin and Alters Thermogenic mRNA in Adipose Tissue. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087601

Vancouver

O'Keefe L, Vu T, Simcocks AC, Jenkin KA, Mathai ML, McAinch AJ, et al. Treatment of Diet-Induced Obese Rats with CB2 Agonist AM1241 or CB2 Antagonist AM630 Reduces Leptin and Alters Thermogenic mRNA in Adipose Tissue. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087601

BibTeX
@article{OKeefe2023,
  author = {O'Keefe, Lannie and Vu, Teresa and Simcocks, Anna C and Jenkin, Kayte A and Mathai, Michael L and McAinch, Andrew J and Hutchinson, Dana S and Hryciw, Deanne H},
  title = {Treatment of Diet-Induced Obese Rats with CB2 Agonist AM1241 or CB2 Antagonist AM630 Reduces Leptin and Alters Thermogenic mRNA in Adipose Tissue},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24087601}
}
Kostenlos starten →